Earnings Material +

Curaleaf Reports First Quarter 2026 Results: Robust Growth and Net Income

Curaleaf Turns Profitable as Debt Wall Moves, Auditor Switch Raises Eyebrows

By The Northwire Desk — AI Analysis May 05, 2026 · 16:01 CURA · 4.45 CURALEAF HOLDINGS, INC. J

Executive Summary

Q1 2026 Financials: Reported net revenue of $324.2 million (up 6% YoY) and Net Income from continuing operations of $70.1 million ($0.09 per share), a significant turnaround from Q4 2025's net loss of $(49.3) million.
Profitability Metrics: Gross profit margin held at 49%; Adjusted EBITDA was $63.4 million (19.6% margin). Operating cash flow was $21.3 million; Free cash flow was $4.3 million.
Capital Structure: Closed a $500 million private placement of non-dilutive senior secured notes due February 2029 at 11.5% interest to fully repay outstanding Senior Secured Notes - 2026. Cash balance ended quarter at $106.1 million.
M&A Activity: Completed the buyout of the remaining 45% equity interest in Four 20 Pharma (German subsidiary), achieving 100% ownership.
Operations: Expanded Florida retail footprint to 72 locations; opened adult-use dispensary in Bangor, ME; expanded Ohio presence with two new dispensaries. Launched "Select Briq 2" and "Dark Heart" brands.
Governance Changes: Appointed Torsten Greif (co-founder of Four 20 Pharma) to the Board. Announced change of auditors from PKF O'Connor Davies to BDO USA, P.C.

Material Impact

Profitability Turnaround: The shift from a net loss in Q4 2025 to $70.1 million net income in Q1 2026 is material. However, critical analysis suggests this may be driven by non-recurring items related to the debt refinancing completed in February 2026 (gain on extinguishment) rather than purely operational cash flow improvement. Adjusted EBITDA ($63.4M) remains consistent with Q4 2025 ($69M), indicating core operations are stable but not exploding.
Debt Extension: Securing $500 million in capital until 2029 removes immediate refinancing risk (previous notes were due Dec 2026). This is a material positive for solvency, though the 11.5% interest rate remains high cost of capital compared to traditional sectors.
Strategic Consolidation: Full ownership of Four 20 Pharma improves margin potential in Europe by removing minority partner drag and aligning supply chain (Portugal/Canada cultivation to German distribution). This was announced April 30, so the May 5 news confirms completion rather than breaking new ground.
Auditor Change: The switch from PKF O'Connor Davies to BDO is a notable risk signal. While often routine, in a high-risk sector like cannabis, it warrants scrutiny regarding internal controls or accounting disputes. This tempers the positive sentiment for a risk-averse investor.
Market Reaction: The stock has recovered from March 2026 lows ($2.64) to current levels (~$4.45), pricing in much of the debt refinancing and profitability news.

CURA · Price

Company Overview

Overview: Curaleaf is one of the largest vertically integrated cannabis operators in North America and Europe, with significant retail presence in Florida, Ohio, and Massachusetts, plus medical operations in Germany (Four 20 Pharma).
Flagship Project: The "Return to Our Roots" strategy focuses on core high-margin markets (FL, OH, MA) and international expansion via Four 20 Pharma. The flagship project is the integration of European cultivation (Portugal/Canada) with German distribution to maximize margins in the EU medical market.
Development Status: The company has successfully refinanced near-term debt obligations and consolidated its European subsidiary. Retail footprint continues to expand incrementally in key US states.

More from CURALEAF HOLDINGS, INC. J